GlassScriptPhysician profile
Allen Hsieh
NPI 1912992769
$2,071.81
in general payments reported to CMS, 2019-2025
23 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $109 · 2021: $13.62 · 2022: $265 · 2023: $291 · 2024: $331 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $412.28 | 2019-2025 | |
| Amgen INC. | $316.75 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $174.26 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $156.09 | 2019 | |
| Boston Scientific Corporation | $134.78 | 2023-2024 | Watchman Flx, Watchman, Watchman Access System |
| Merck Sharp & Dohme LLC | $129.66 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $106.96 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.72 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.15 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $76.70 | 2024-2025 | |
| Biosense Webster, INC. | $65.25 | 2019 | |
| Azurity Pharmaceuticals, INC. | $52.95 | 2024-2025 | Edarbyclor |
| Regeneron Healthcare Solutions, INC. | $49.43 | 2019 | |
| Novo Nordisk INC | $29.45 | 2022-2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $28.79 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $28.42 | 2019 | |
| Impulse Dynamics (USA) INC. | $26.11 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.66 | 2025 | Lifevest |
| Atricure, INC. | $19.70 | 2025 | Atriclip Laa Exclusion System |
| Alnylam Pharmaceuticals INC. | $17.98 | 2023 | Onpattro |
| Glaxosmithkline, LLC. | $17.64 | 2025 | Arexvy, Shingrix |
| Irhythm Technologies, INC. | $16.37 | 2019 | |
| Esperion Therapeutics, INC. | $14.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Hsieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.